Upload
finance12
View
2.175
Download
8
Tags:
Embed Size (px)
DESCRIPTION
Citation preview
Deutsche Bank Deutsche Bank Health Care ConferenceHealth Care Conference
Cavan M. Redmond Executive Vice President, General ManagerBioPharma Business Unit
May 3, 2007
Forward-Looking Statement
The statements in this presentation that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, the impact of competitive or generic products, product liability and other types of lawsuits, the impact of legislative and regulatory compliance and obtaining approvals, and patent, and other risks and uncertainties, including those detailed from time to time in Wyeth’s periodic reports, including quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Quarterly results, in particular, can vary due to issues which include, but are not limited to, changes in exchange rates, the timing of actions taken by the Company to ensure long-term improvements to our manufacturing processes, the timing of regulatory approval of new products and/or facilities and the timing of promotional programs. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Ability to GloballyCommercialize Products
Ability to Create a Sustainable Biotech R&D Pipeline
Expertise in Process Development and Commercial Manufacturing
Biotechnology: Three Key Areas for Success
Biotech’s Unique Position in Healthcare
n Only 227 Commercial Biotech Products on the Market Today
n The Top 10 Biotech Companies Accounted for 100 of the 227 Biotech Products on the Market in 2006
n Ex-US Markets Have Become Important Biotech Markets
n Wyeth Has Two Top 20 Biotech Products: 4Enbrel
4Prevnar
Biotech Industry – Top 10 CompaniesWyeth Ranks 4th in Audited Sales
Source: Market Insights; IMS Quarterly Midas; Biotech industry based on definition by biotechnology industry organization, www.bio.org.*Enbrel for North America included in both Wyeth and Amgen; however, industry number does not double count Enbrel.
MAT/12/2006Rank
MAT/12/2006 (000's)
Total Biotech Industry $ 76,535,257 Top 10 Biotech Companies $ 54,302,797 AMGEN 1 15,895,830$ ROCHE 2 13,342,857$ JOHNSON & JOHNSON 3 6,751,136$ WYETH+ENBREL* 4 6,275,683$ NOVARTIS 5 3,055,300$ NOVO NORDISK 6 3,041,482$ GILEAD SCIENCES 7 2,331,733$ LILLY 8 2,265,241$ SANOFI-AVENTIS 9 2,156,318$ SCHERING-PLOUGH 10 2,149,310$
Wyeth is 3rd of Top 10 Pharma Companies in Biotech Audited Sales as a Percentage of the Business
Source: Market Insights; IMS Quarterly Midas; Biotech industry based on definition by Biotechnology Industry Organization, www.bio.org.
*Enbrel for North America included in both Wyeth and Amgen; however, industry number does not double count Enbrel.
MAT/12/2006Rank
MAT/12/2006 ('000's)
Percent Biotech
Global Rx Industry $ 552,691,651 14%Global Biotech Industry $ 76,535,257 NA
PFIZER 1 45,061,752$ 2% GLAXOSMITHKLINE 2 35,134,973$ 3% SANOFI-AVENTIS 3 29,058,798$ 7% NOVARTIS 4 28,826,878$ 11% ASTRAZENECA 5 26,389,075$ 0% MERCK & CO 6 24,734,873$ 1% JOHNSON & JOHNSON 7 22,662,100$ 30% ROCHE 8 21,371,780$ 62% WYETH+ENBREL+ALTACE* 9 17,971,027$ 35% AMGEN 10 15,992,680$ 99% ABBOTT 11 15,912,513$ 13%
Wyeth Biotech Worldwide Revenue
$1.7 Billion – 1Q2007
Biotech Reported Solid Results for 1Q07
1Q07 + 39%
1Q07 vs.1Q06
GROWTH
Wyeth Biotech Results2007 1Q
Latin Latin AmericaAmerica
92%92%
Wyeth Biotech – A Global Reach2007 1Q Results
US Region$847M
Asia Asia PacificPacific
16%16%
Asia Pacific$83M
EMEAEMEA--CanadaCanada$702M$702M
Latin America
$73M
US US RegionRegion
45%45%
EMEA EMEA CACA
34%34%
Growth vs. 1Q06
43%33%
13%
Represents 1Q2007 Net Revenue and percentage increase compared with prior year. Infuse/Inductos (BMP) represents Net Revenue reported by Wyeth for US sales recorded by MSD.
49%
$445M
$177M$97M
$617M
Wyeth Biotech Net Revenue Results2007 1Q Key Growth Drivers
(Ex North America)
Wyeth in Biotech: Global Growth Resulting in Two Products Reaching/Exceeding $3 Billion in 2010
n Enbrel: $3 Billion Ex-US 4Market Opportunities
4Geographic and Medical Expansion
4Unique Mechanism of Action With Extensive Safety/Efficacy
n Prevnar: Double Sales From 2005 to 20104Launches in New Countries
4National Immunization Programs
Enbrel – Second Largest Global Biotech Brand (Audited Sales)
MAT/12/2006Rank
MAT/12/2006 ('000's)
Selected Market 76,535,257$ ARANESP 1 4,964,712$ ENBREL 2 4,518,925$ ERYPO 3 3,661,877$ REMICADE 4 3,560,530$ NEULASTA 5 3,249,424$ MABTHERA 6 3,206,692$ EPOGEN 7 3,142,188$
Enbrel Remains One of Top 10 Pharmaceutical Products Worldwide
Prevnar®
Launched in 76 CountriesLaunched in 76 Countries
Additional 9 Launchesby 2008
National Immunization Programs
n United Statesn Australian Canadan Francen Germanyn Greecen Kuwaitn Luxembourg
n Austrian Denmarkn Finlandn Hong Kongn Icelandn Irelandn Japann Taiwan
n New Zealandn Portugaln Saudi Arabian Singaporen South Korean Spainn Swedenn Costa Rica
Potential NIPs
Total Birth Cohort ~10 Million Total Birth Cohort ~3 Million
n Netherlandsn Norwayn Qatarn Switzerlandn United Kingdomn Mexicon Italyn Belgium
Current NIPs
Emerging Market Opportunities
Private to Potential NIPsn Chile
n China
n Ecuador
n Hungary
n India
n Indonesia
n Malaysia
n Pakistan
n Peru
n Philippines
n Romania
n Russia
n South Africa
n Thailand
n Uruguay
n Argentina
n Brazil
n Colombia
n Czech Republic
n Poland
n Turkey
n Venezuela
Private Markets
Total Birth Cohort ~8 Million Total Birth Cohort ~58 Million
Hemophilia Franchise: Driving New Innovation
n Recombinant FVIII
n ReFacto AF4New Albumin-Free ReFacto 4Manufactured Using No
Human or Animal Products 4Filed 2Q07
n Additional Convenience Devices to Meet Patient’s Needs
n The Only Recombinant Factor IX
n A New Formulation of BeneFIX Expected to Launch Mid-20074Key Additional Convenience
Devices to Meet Patient’s Needs
n Full European Rights Revert to Wyeth in July 2007
BMP-2: Innovating Biotech & Devices
n Revolutionary Product Meeting Significant Medical Needs
n Oral Maxillofacial Procedures4 Approved by FDA in March 2007
n AMPLIFY for PosterolateralSpinal Fusion
4 Submitted to and Accepted by FDA in Q1 2006
$0
$100
$200
$300
$400
$500
$600
$700
2003 2004 2005 2006
+ 102%
+ 41%
+ 30%
CAGR: ~50%
$ m
il
INFUSE Sales(As Reported by Medtronic)
2002: Spinal Fusion
2004: Open Tibia Fracture
Indications
Andover, MAAndover, MA
Sanford, NCSanford, NC
Algete, SpainAlgete, Spain
Pearl River, NYPearl River, NY
Grange Castle, IrelandGrange Castle, Ireland
Biology Over Stainless Steel
n Our Current Investments Are in Process Standardization and Upstream/Downstream Process Efficiencies and Yields
n Upstream: Proprietary Position on Enhancing Cell Culture Yields With Defined Media (2004)4 “Wyeth Recently Created a Cell Culture System
That Can Generate 9 Grams of Protein Per Liter of Culture. Just Four Years Ago, the Standard Was 1 Gram Per Liter.” Nature Biotechnology, September 2006
n We Are Focused on Further CHO Cell Improvement Through Genetic and Metabolic Engineering (Gene Chip)
CHO Chip Scan
Changing the Paradigm of Biotech Manufacturing Capacity
n DOWNSTREAM: Proprietary Position on Two-Column Purification for Mabs (2005)
n All Proprietary Processes Incorporated Into Standardized Platform4 Speed to IND and Launch
n 10 Metric Tons of Theoretical Capacity From Standard Facilities4 Or 1 Metric Ton X 4 Products -
Sept 2006 ACS in SF
n Transforms the Thinking on Cost Structure and Importance of Volumetric Capacity
CME-548AAB-002TRU-015 (Onc)IMA – 026ILV-095RAS -072SBI -087BLD-089BMP-12BHS-019ACC-002HIV Vaccine (4)Staph aureus
Inotuzumab/ (CMC-544)IMA-638ILV-094MnB Infant ACC-001
Bapineuzumab GAP-486TRU-015 (RA)BMP-2 Inject.MYO-029MnB Adolescent
Mylotarg® – AMLTorisel™
ReFacto® AF
ProteinsVaccines
13vPnC Infant13vPnC Adult
Phase 0Phase 0 Phase 1Phase 1 Phase 2Phase 2 Phase 3Phase 3 RegistrationRegistration
Our Discovery Pipeline Continues To Grow
A Robust Biotech Pipeline Contributing to Future Growth
n 1/3 of Current Pipeline Is Biotech and Vaccines
n Combination of In-house and In-licensing
n Broad Therapeutic Coverage4 Immunology
4 Vaccines
4 Oncology
4 Bone Growth
4 Neuroscience
4 Hemophilia
Biotech at Wyeth – A Look At the Future
200020002000
14%14%14% 200620062006
33%33%33% 2010 (est.)
2010 2010 (est.)(est.)
45%45%45%